Table 3b:
Continued or new symptoms | Symptomatic but functional n=58 n (%) |
Symptomatic and limited n=18 n (%) |
X 2 p-value |
---|---|---|---|
Muscle or Joint Aches | 8 (15) | 6 (33) | <0.0001 |
Shortness of Breath | 3 (6) | 11 (61) | <0.0001 |
Persistent cough | 3 (6) | 2 (12) | <0.0001 |
Lower energy/Increased tiredness | 12 (22) | 17 (94) | <0.0001 |
Cannot walk long distances | 2 (4) | 8 (44) | <0.0001 |
Cannot walk up stairs | 3 (6) | 8 (44) | <0.0001 |
Cannot exercise like I did before | 5 (9) | 10 (55) | <0.0001 |
New heart problems | 5 (9) | 5 (28) | <0.0001 |
Loss of Smell | 20 (37) | 5 (28) | <0.0001 |
Loss of Taste | 12 (22) | 2 (11) | <0.0001 |
Brain Fog/Inability to concentrate | 7 (13) | 10 (55) | <0.0001 |
Anxiety | 1 (2) | 4 (22) | <0.0001 |
Stress | 0 (0) | 3 (17) | <0.0001 |
Data are self-reported by participants at the time of interview, which occurred a median of 5.9 months after positive SARS-CoV-2 RNA test